Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21472794 | 0.87 | PKM (0.47) | ALDH1A1MAPTL3MBTL1MCL1GAA | |
| SCHEMBL21472729 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTL3MBTL1MCL1POLB | |
| SCHEMBL21472705 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTL3MBTL1MCL1HTT | |
| SCHEMBL24806454 | 0.85 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1MCL1HTT | |
| SCHEMBL21231248 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MAPTL3MBTL1MCL1HTT | |
| SCHEMBL21472725 | 0.83 | HPGD (0.46) | ALDH1A1MAPTPOLBGAAHPGD | |
| SCHEMBL21230889 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MAPTL3MBTL1MCL1HTT | |
| SCHEMBL24937898 | 0.76 | PKM (0.46) | ALDH1A1MAPTL3MBTL1MCL1GAA | |
| SCHEMBL23419612 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1MCL1HPGD | |
| SCHEMBL21842771 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MAPTL3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MordernaTX, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885MAPT 2478/4885L3MBTL1 869/4885 |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885MAPT 2478/4885L3MBTL1 869/4885 |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | ALDH1A1 4722/4885MAPT 2204/4885L3MBTL1 595/4885 |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ALDH1A1 4530/4885MAPT 2478/4885L3MBTL1 869/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | ALDH1A1 115/4885MAPT 3072/4885L3MBTL1 1986/4885 |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | ALDH1A1 4722/4885MAPT 2204/4885L3MBTL1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.